Amphastar Pharmaceuticals, Inc. (FRA:29A)

Market Cap	798.79M -26.7%
Revenue (ttm)	613.13M -1.7%
Net Income	83.55M -38.5%
EPS	1.73 -33.7%
Shares Out	n/a
PE Ratio	9.56
Forward PE	6.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	17.33
Previous Close	17.64
Day's Range	17.33 - 17.33
52-Week Range	15.26 - 25.96
Beta	n/a
RSI	47.23
Earnings Date	May 7, 2026

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the preven...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 1,976
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 29A

Financial Performance

In 2025, Amphastar Pharmaceuticals's revenue was $719.89 million, a decrease of -1.65% compared to the previous year's $731.97 million. Earnings were $98.09 million, a decrease of -38.51%.

Financial numbers in USD